Literature DB >> 32112899

Korean red ginseng attenuates hyperglycemia-induced renal inflammation and fibrosis via accelerated autophagy and protects against diabetic kidney disease.

Shanika Karunasagara1, Geum-Lan Hong1, Se-Ra Park2, Na-Hyun Lee1, Da-Young Jung1, Tae-Won Kim1, Ju-Young Jung3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Panax ginseng C.A. Mey. (Korean ginseng) has been widely used in traditional medicine to treat diabetes mellitus for thousands of years. It also plays a key role in health maintenance owing to its anti-oxidant and anti-fatigue properties, and is quite popular as a dietary supplement. AIM OF THE STUDY: This study was designed to offer a complementary and alternative medicine to manage the diabetic kidney disease (DKD), which causes long-term damage to the renal structure. We also investigated the regulation of the autophagy mechanism, which is the underlying the pathogenesis of DKD.
MATERIALS AND METHODS: The effect of Korean red ginseng (KRG) on DKD was evaluated using human kidney proximal tubular cells and streptozotocin (STZ)-treated Sprague-Dawley rat models. In vitro experiments were conducted to evaluate the proteins related to fibrosis and autophagy. This was followed by in vivo experiments involving rats treated with single intraperitoneal administration of STZ (60 mg/kg) and then with KRG solution orally for 4 weeks. Proteins related to renal injury, fibrosis, and autophagy were determined by immunoblotting. Hematoxylin and eosin (H&E), Periodic acid-Schiff (PAS), Sirius red, and immunostaining were processed for histological studies.
RESULTS: KRG diminished the levels of metabolic measurements and blood parameters. Western blotting showed a decreased expression of proteins, such as TGF-β1, KIM1, and AGE, which are responsible for renal inflammation, injury, and fibrosis. Histological studies also supported these results and revealed that the KRG-treated groups recovered from renal injury and fibrosis. Furthermore, the autophagy marker, LC3, was upregulated, whereas p62 was downregulated. The levels of proteins related to the autophagy mechanism, such as ATG7, increased, while mammalian target of rapamycin (mTOR) decreased with the KRG treatment and exhibited accelerated autophagy compared to the STZ alone group.
CONCLUSIONS: KRG can suppress renal inflammation, injury, and fibrosis by blocking TGF-β1 activation and can induce cellular autophagy. Therefore, this study strongly suggests that KRG exhibits a renoprotective effect against the STZ-induced DKD.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetic kidney disease; Korean red ginseng; LC3; Streptozotocin; TGF-β1

Mesh:

Substances:

Year:  2020        PMID: 32112899     DOI: 10.1016/j.jep.2020.112693

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

Review 1.  Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.

Authors:  Hao Liu; Chongning Lv; Jincai Lu
Journal:  Chin Med       Date:  2020-11-24       Impact factor: 5.455

2.  The Effect of a 2-Week Red Ginseng Supplementation on Food Efficiency and Energy Metabolism in Mice.

Authors:  Hyejung Hwang; Jisu Kim; Kiwon Lim
Journal:  Nutrients       Date:  2020-06-09       Impact factor: 5.717

3.  Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy.

Authors:  Wei Lv; Mei-Rong Wang; Cheng-Zhen Zhang; Xue-Xu Sun; Zhen-Zhen Yan; Xiao-Min Hu; Tao-Tao Wang
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

Review 4.  The critical role of dysregulated autophagy in the progression of diabetic kidney disease.

Authors:  Ziwei Zhang; Yuting Sun; Jiaojiao Xue; Xiangyan Li; Daqing Zhao; Fengmei Lian; Wenxiu Qi; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 5.  NADH/NAD+ Redox Imbalance and Diabetic Kidney Disease.

Authors:  Liang-Jun Yan
Journal:  Biomolecules       Date:  2021-05-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.